- Previous Close
12.30 - Open
12.16 - Bid 12.02 x 200
- Ask 12.08 x 100
- Day's Range
11.81 - 12.27 - 52 Week Range
8.51 - 17.79 - Volume
391,528 - Avg. Volume
613,052 - Market Cap (intraday)
690.06M - Beta (5Y Monthly) 2.03
- PE Ratio (TTM)
-- - EPS (TTM)
-2.04 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.43
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
olema.comRecent News: OLMA
View MorePerformance Overview: OLMA
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OLMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OLMA
View MoreValuation Measures
Market Cap
690.06M
Enterprise Value
452.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.47%
Return on Equity (ttm)
-56.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-109.63M
Diluted EPS (ttm)
-2.04
Balance Sheet and Cash Flow
Total Cash (mrq)
239.1M
Total Debt/Equity (mrq)
0.86%
Levered Free Cash Flow (ttm)
-44.97M
Research Analysis: OLMA
View MoreCompany Insights: OLMA
OLMA does not have Company Insights